Ask AI
ProCE Banner Activity

MONARCH vs MOBILITY: Similar Efficacy With Sarilumab ± MTX in MTX-IR/INT RA

Conference Coverage
Slideset

In cross-trial post hoc analysis with mixed-effect model repeated measure adjustment, no evident differences in Week 24 endpoints (CDAI, DAS28-CRP, CRP, hemoglobin, pain VAS, FACIT-Fatigue) between patients receiving sarilumab with vs without MTX.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp